NCT06685237 Copenhagen Heart Failure With Preserved Ejection Fraction
| NCT ID | NCT06685237 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tor Biering-Sørensen |
| Condition | Heart Failure With Preserved Ejection Fraction (HFPEF) |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2025-02-28 |
| Primary Completion | 2025-11-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2025-02-28 with a primary completion date of 2025-11-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure (HF) worldwide, in tandem with ageing of the general population and the increasing prevalence of obesity, diabetes mellitus and hypertension. In 2020, \> 70% of patients with heart failure had preserved ejection fraction. The incidence and prevalence of HFpEF has been growing by 10% every 10 years relative to HF with reduced ejection fraction (HFrEF). In 2017, the prevalence of HFpEF varied from 1% to 14% based on available data from Europe and USA. HFpEF is associated with high morbidity and mortality, and patients with HFpEF have similarly high hospitalization rates as patients with HFrEF. Hence, HFpEF poses a substantial global health challenge. Despite its prevalence, HFpEF remains undiagnosed and underrecognized, necessitating a comprehensive approach to both identification and management. Ensuring successful treatment necessitates early identification of HFpEF. Consequently, a targeted screening strategy has been devised for the identification of HFpEF patients. Given the higher prevalence of heart failure (HF) in the elderly population, testing the screening strategy is imperative to customize it to the specific needs of vulnerable patients who may be more inclined to decline participation in the screening program.
Eligibility Criteria
Inclusion Criteria: 1. Residence in the Capital Region of Denmark 2. Age ≥ 50 years 3. At least two risk factors for HFpEF defined as any of the following (for age ≥ 60 years, only one): * Hypertension * Diabetes mellitus * Chronic kidney disease * Atrial fibrillation * BMI \> 25 kg/m2 * Previous heart valve surgery * Ischemic heart disease * Obstructive sleep apnea * Furosemide 40 mg Exclusion Criteria: 1. Age ≥ 90 years 2. Prevalent HF 3. Dementia 4. Nursing home 5. Amyloidosis 6. Hemodialysis 7. Cancer diagnosed within the past 5 years (skin cancer not included) 8. Prior solid organ transplantation 9. Lung disease defined as any of the following: * World Health Organization Group 1 pulmonary hypertension * Chronic pulmonary embolism * Lung fibrosis * Chronic obstructive pulmonary disease (COPD) * Home oxygen
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06685237 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 89 Years, studying Heart Failure With Preserved Ejection Fraction (HFPEF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06685237 currently recruiting?
Yes, NCT06685237 is actively recruiting participants. Contact the research team at camilla.ikast.ottosen@regionh.dk for enrollment information.
Where is the NCT06685237 trial being conducted?
This trial is being conducted at Hellerup, Denmark.
Who is sponsoring the NCT06685237 clinical trial?
NCT06685237 is sponsored by Tor Biering-Sørensen. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.